New biomarker study aims to track kidney disease severity
NCT ID NCT04630613
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study is looking for markers in urine and blood that can show how severe autosomal dominant polycystic kidney disease (ADPKD) is in its early stages. Researchers will measure NOX4, mitochondrial DNA, and other substances in 60 people aged 15-40 with early ADPKD. The goal is to find better ways to track the disease, not to test a new treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Mayo Clinic
RECRUITINGRochester, Minnesota, 55905, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can brain training lift the weight of depression in kidney disease?
- Thyroid hormones may hold clues to kidney disease progression
- Could zapping kidney nerves tame tough blood pressure in polycystic kidney disease?
- New study links blood markers to kidney disease progression in ADPKD
- Diabetes drug metformin tested as new weapon against kidney disease
- Parkinson's drug repurposed to fight kidney disease?